Mariana Mesquita Fonseca

Ms. Mariana Mesquita Fonseca

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

12 April 2016
Verified
Journal Article
Open access
MFMariana Mesquita Fonseca
Mariana Mesquita Fonseca
TPTaíse Fonseca Pedroso
Taíse Fonseca Pedroso
Cláudia Sirlene OliveiraCláudia Sirlene Oliveira
Cláudia Sirlene Oliveira
VOVitor A. Oliveira
Vitor A. Oliveira
RSRafael Francisco Do Santos
Rafael Francisco Do Santos
MPMaria Ester Pereira
Maria Ester Pereira
This work investigated the toxicity of inorganic mercury and zinc preventive effects in female rats sacrificed 12 or 48 h after HgCl2 exposure. Female Wistar rats were subcutaneously injected with ZnCl2 (27 mg/kg) or saline (0.9 %), and 24 h later they were exposed to HgCl2 (5 mg/kg) or saline (0.9 %). Rats sacrificed 12 hours after Hg administration presented an increase in kidney weight and a decrease in renal ascorbic acid levels. Zinc pretreatment prevented the renal weight increase. Rats sacrificed 48 h after Hg exposure presented a decrease in body weight gain, an increase in renal weight, a decrease in renal δ-aminolevulinic acid dehydratase activity, an increase in serum creatinine and urea levels, and a decrease in kidney total thiol levels. Zinc pretreatment partly prevented the decrease in body weight gain and increase in creatinine levels, in addition to totally preventing renal δ-aminolevulinic acid dehydratase inhibition. Mercury accumulation in the kidney and liver in both periods was observed after Hg administration. These results show the different Hg effects along the time of intoxication, and a considerably preventive effect of zinc against Hg toxicity.

1 October 2015 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
VOVitor Antunes Oliveira
Vitor Antunes Oliveira
Cláudia Sirlene OliveiraCláudia Sirlene Oliveira
Cláudia Sirlene Oliveira
MFMariana Mesquita Fonseca
Mariana Mesquita Fonseca
TPTaíse Fonseca Pedroso
Taíse Fonseca Pedroso
LCLidiane Machado Costa
Lidiane Machado Costa
MPMaria Ester Pereira
Maria Ester Pereira

7 April 2017 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
TPTaíse Fonseca Pedroso
Taíse Fonseca Pedroso
Cláudia Sirlene OliveiraCláudia Sirlene Oliveira
Cláudia Sirlene Oliveira
MFMariana Mesquita Fonseca
Mariana Mesquita Fonseca
VOVitor A. Oliveira
Vitor A. Oliveira
MPMaria Ester Pereira
Maria Ester Pereira

1 October 2016 in Reproductive Toxicology
Verified
Journal Article
Closed access
Cláudia Sirlene OliveiraCláudia Sirlene Oliveira
Cláudia Sirlene Oliveira
VOVitor A. Oliveira
Vitor A. Oliveira
LCLidiane M. Costa
Lidiane M. Costa
TPTaíse Fonseca Pedroso
Taíse Fonseca Pedroso
MFMariana Mesquita Fonseca
Mariana Mesquita Fonseca
MPMaria E. Pereira
Maria E. Pereira

5 October 2024 in JHEP Reports
Verified
Journal Article
Open access
ALArantza Lamas-Paz
Arantza Lamas-Paz
AHAlejandro Hionides-Gutiérrez
Alejandro Hionides-Gutiérrez
FGFeifei Guo
Feifei Guo
GJGonzalo Jorquera
Gonzalo Jorquera
LMLaura Morán-Blanco
Laura Morán-Blanco
Francisco Javier CuberoFrancisco Javier Cubero
Francisco Javier Cubero
Expression of P21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD); however, the underlying mechanisms remain unknown. In the present study, we investigated the function of CDKN1A in SLD. CDKN1A expression levels were evaluated in different patient cohorts with SLD, fibrosis, and advanced chronic liver disease (ACLD). Cdkn1a -/- and Cdkn1a +/+ mice were fed with either a Western diet (WD), a Lieber-DeCarli (LdC) diet plus multiple EtOH (ethanol) binges, or a DuAL diet (metabolic dysfunction-associated fatty liver disease and alcohol-related liver). Primary hepatocytes were isolated and functional assays performed. A significant increase in CDKN1A expression was observed in patients with steatohepatitis and fibrosis (with a positive correlation with both NAFLD Activity Score and fibrosis staging scores), cirrhosis and ACLD. Cdkn1a +/+ mice, fed a DuAL diet exhibited liver injury and cell death increased reactive oxygen species (ROS), and markers of senescence (γH2AX, β-GAL, Cdkn1a/p53) contributing to steatosis and inflammation. In contrast, Cdkn1a -/- mutant mice showed a significant decrease in senescence-associated markers as well as in markers of liver injury, hepatic steatosis and an increase in fatty acid oxidation and reduction in free fatty acid uptake as well as de novo lipogenesis. Mechanistically, activation of the AMPK-SIRT3 was observed in Cdkn1a-deleted animals. Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis via the AMPK-SIRT3 axis. CDKN1A expression was found to be directly correlated with increased severity of NAFLD Activity Score and fibrosis in patients with SLD. CDKN1A could be a potential theragnostic target for the treatment of metabolic dysregulation in patients with SLD, with and without alcohol consumption. Expression of p21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD), but the molecular mechanisms remain elusive. Interestingly, in this study we found that Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis, via the AMPK-SIRT3 axis. Translationally, Cdkn1a expression was found to be directly correlated with increased severity of NAFLD Activity Score (NAS) and fibrosis in SLD patients, and therefore, CDKN1A might be used potential theragnostic target for the treatment of metabolically induced SLD, with and without alcohol consumption.